Cargando…
Exosome: A New Player in Translational Nanomedicine
Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463834/ https://www.ncbi.nlm.nih.gov/pubmed/32722531 http://dx.doi.org/10.3390/jcm9082380 |
_version_ | 1783577224547401728 |
---|---|
author | Aheget, Houssam Tristán-Manzano, María Mazini, Loubna Cortijo-Gutierrez, Marina Galindo-Moreno, Pablo Herrera, Concha Martin, Francisco Marchal, Juan Antonio Benabdellah, Karim |
author_facet | Aheget, Houssam Tristán-Manzano, María Mazini, Loubna Cortijo-Gutierrez, Marina Galindo-Moreno, Pablo Herrera, Concha Martin, Francisco Marchal, Juan Antonio Benabdellah, Karim |
author_sort | Aheget, Houssam |
collection | PubMed |
description | Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and nucleic acids between cells and organs, as well as their potential to act as natural intercellular communicators in normal biological processes and in pathologies. From a clinical perspective, the majority of applications use exosomes as biomarkers of disease. A new approach uses exosomes as biologically active carriers to provide a platform for the enhanced delivery of cargo in vivo. One of the major limitations in developing exosome-based therapies is the difficulty of producing sufficient amounts of safe and efficient exosomes. The identification of potential proteins involved in exosome biogenesis is expected to directly cause a deliberate increase in exosome production. In this review, we summarize the current state of knowledge regarding exosomes, with particular emphasis on their structural features, biosynthesis pathways, production techniques and potential clinical applications. |
format | Online Article Text |
id | pubmed-7463834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74638342020-09-04 Exosome: A New Player in Translational Nanomedicine Aheget, Houssam Tristán-Manzano, María Mazini, Loubna Cortijo-Gutierrez, Marina Galindo-Moreno, Pablo Herrera, Concha Martin, Francisco Marchal, Juan Antonio Benabdellah, Karim J Clin Med Review Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and nucleic acids between cells and organs, as well as their potential to act as natural intercellular communicators in normal biological processes and in pathologies. From a clinical perspective, the majority of applications use exosomes as biomarkers of disease. A new approach uses exosomes as biologically active carriers to provide a platform for the enhanced delivery of cargo in vivo. One of the major limitations in developing exosome-based therapies is the difficulty of producing sufficient amounts of safe and efficient exosomes. The identification of potential proteins involved in exosome biogenesis is expected to directly cause a deliberate increase in exosome production. In this review, we summarize the current state of knowledge regarding exosomes, with particular emphasis on their structural features, biosynthesis pathways, production techniques and potential clinical applications. MDPI 2020-07-26 /pmc/articles/PMC7463834/ /pubmed/32722531 http://dx.doi.org/10.3390/jcm9082380 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Aheget, Houssam Tristán-Manzano, María Mazini, Loubna Cortijo-Gutierrez, Marina Galindo-Moreno, Pablo Herrera, Concha Martin, Francisco Marchal, Juan Antonio Benabdellah, Karim Exosome: A New Player in Translational Nanomedicine |
title | Exosome: A New Player in Translational Nanomedicine |
title_full | Exosome: A New Player in Translational Nanomedicine |
title_fullStr | Exosome: A New Player in Translational Nanomedicine |
title_full_unstemmed | Exosome: A New Player in Translational Nanomedicine |
title_short | Exosome: A New Player in Translational Nanomedicine |
title_sort | exosome: a new player in translational nanomedicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463834/ https://www.ncbi.nlm.nih.gov/pubmed/32722531 http://dx.doi.org/10.3390/jcm9082380 |
work_keys_str_mv | AT ahegethoussam exosomeanewplayerintranslationalnanomedicine AT tristanmanzanomaria exosomeanewplayerintranslationalnanomedicine AT maziniloubna exosomeanewplayerintranslationalnanomedicine AT cortijogutierrezmarina exosomeanewplayerintranslationalnanomedicine AT galindomorenopablo exosomeanewplayerintranslationalnanomedicine AT herreraconcha exosomeanewplayerintranslationalnanomedicine AT martinfrancisco exosomeanewplayerintranslationalnanomedicine AT marchaljuanantonio exosomeanewplayerintranslationalnanomedicine AT benabdellahkarim exosomeanewplayerintranslationalnanomedicine |